Warning letter
Velocity Pharma LLC: warning letter of Jul 17, 2024
FDA warning letter 676434 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 676434 |
|---|---|
| Company | Velocity Pharma LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jul 17, 2024 |
| Posted date | Aug 6, 2024 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| Inspection city | Melville |
| Inspection ZIP | 11747 |
| Inspection start date | Nov 3, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: